1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
SomnoMed Limited

SomnoMed Limited

SOMNF
SomnoMed LimitedUS flagOther OTC
0.45
USD
-NaN
- -
98.59MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
0.23
0.27
0.38
0.46
0.58
0.58
0.73
0.64
0.67
0.59
0.68
0.79
0.76
Basic EPS, GAAP
0.01
0.01
0.01
0.01
- -
-0.04
-0.1
-0.18
-0.01
-0.01
-0.04
-0.08
-0.1
Free Cash Flow per Basic Share
- -
- -
-0.02
-0.02
- -
-0.06
-0.02
-0.02
-0.03
-0.04
-0.08
-0.06
-0.04
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.12
0.13
0.15
0.24
0.38
0.33
0.34
0.11
0.3
0.23
0.19
0.11
0.3
Tangible Book Value per Share
0.1
0.08
0.02
0.15
0.36
0.34
0.32
0.14
0.34
0.22
0.12
0.05
0.21
Basic Weighted Avg Shares
66
68
68
75
77
85
88
91
85
106
106
106
121
Sales/Revenue/Turnover
15
18
26
34
44
49
64
59
57
63
73
84
92
Operating Margin (%)
2.99
1.11
1.22
0.12
0.15
-7.57
-13.94
1.56
-1.64
-1.36
-5.69
-4.87
-9.09
Depreciation Expense
- -
1
1
1
1
1
2
1
3
4
4
5
6
Net Income, GAAP
1
1
- -
1
- -
-3
-9
-16
-1
-1
-4
-8
-12
Effective Tax Rate (%)
- -
- -
6.74
23.53
86.31
- -
- -
106.49
158.68
- -
- -
- -
- -
Profit Margin (%)
3.42
3.18
1.57
1.73
0.37
-6.78
-13.55
-27.91
-1.95
-1.9
-6.11
-9.57
-13.36
Working Capital
5
5
6
14
22
20
20
3
24
18
3
11
19
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
8
7
5
21
4
Total Equity
9
12
13
23
35
35
35
20
37
32
28
25
46
Return on Invested Capital (%)
- -
- -
2.32
0.17
0.03
- -
- -
-0.18
1.36
- -
- -
- -
- -
Return on Capital (%)
- -
- -
6.29
4.8
1.14
- -
- -
-73.43
-4.23
- -
- -
- -
- -
Return on Common Equity (%)
8.09
7.31
4.4
4.31
0.71
-11.83
-29.83
-81.94
-6.32
-4.8
-20
-50.07
-51.36

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.4%
25.92%
87.34%
Free Cash Flow
-549.12%
37.89%
-16.74%
Net Income, GAAP
-158.46%
63.74%
53.04%
Sales/Revenue/Turnover
14.17%
9.46%
9.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
73
2023
- -
- -
- -
- -
84
2024
- -
- -
- -
- -
92

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.04
2023
- -
- -
- -
- -
-0.08
2024
- -
- -
- -
- -
-0.1

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Amrita Blickstead
Full Time Employees
461
Sector
Healthcare
Industry
Medical - Devices
Address
20 Clarke Street Crows Nest NSW Australia 2066
IPO Date
Oct 15, 2010
Website
somnomed.com
Similar Companies
Beijing Chunlizhengda Medical Instruments Co., Ltd. (688236.SS)
Cell MedX Corp. (CMXC)
Align Technology, Inc. (0HCK.L)
Owlet, Inc. (OWLT-WT)
Medartis Holding AG (MED.SW)
Hyperion DeFi, Inc. (HYPD)
Business
SomnoMed Limited operates as a medical technology enterprise, delivering advanced oral solutions for sleep-related breathing conditions across multiple international markets, including Europe, North America, and the Asia Pacific region. The company's primary offerings include its clinically proven SomnoDent line of custom-fitted oral appliances, designed to effectively manage obstructive sleep apnea by gently repositioning the jaw. Complementary products consist of the SomnoBrux dental guard for addressing teeth grinding, the SomMorning Repositioner to aid mandibular return, and SomTabs for device cleaning. Further enhancing its portfolio, SomnoMed is actively advancing its Rest Assure platform, an innovative tech-enabled oral appliance integrating biosensor technology for objective treatment data. Established in 2004, the firm maintains its corporate headquarters in Sydney, Australia.

Company News

APIChatGPT

  • seekingalpha.com

    SomnoMed Limited (SOMNF) Q2 2026 Earnings Call Transcript